# Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

> **NCT06740825** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 32 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Rufinamide

## Key facts

- **NCT ID:** NCT06740825
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-29
- **Primary completion:** 2024-12-09
- **Final completion:** 2024-12-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06740825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06740825, "Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06740825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*